Jay Prensky: The PALADIN Real-World Observational Study

Video

Jay Prensky, MD, talks about the results of the PALADIN real-world study and the use of the fluocinolone acetonide 0.2 ug/day implant in DME patients.

Jay Prensky, MD, FACS: Well, we found that there was a significant reduction in treatment burden, over the first 6 months anyway, compared to what was historical for these patients. They were receiving injections from every 2 to 3 months. But overall, it showed that it was a safe and efficacious drug that may have some long-term benefit in terms of treatment burden.

Also, in spite of the average duration of diabetic macular edema prior to receiving the Iluvien implant, of a 5-year duration, there were still patients that were gainers, and I mean I thought that was pretty impressive considering these people had been treated for long, long periods of time prior to receiving the implant.

So basically, a third of patients that have received the fluocinolone implant, that had visual acuities of 20/40, went on to receive an average of 2 further injections in that 6 months. But, that left 67% of patients with 20/40 vision that had no further injections. The treatment burden appears to be significantly reduced and it appears to be safe and effective and, at visual acuities, there was a positive result with visual acuity improvement. Small with better visions - and this may be a ceiling effect - and a greater visual acuity improvement for those that had poorer vision to start.

Related Videos
Deepak Sambhara, MD | Image Credit: American Society of Retina Specialists
David Brown, MD | Image Credit: Retina Consultants of Texas
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Building a Psoriasis Knockout Regimen Around Risankizumab, with Andrew Blauvelt, MD, MBA
Joel Gelfand, MD, MSCE: Phototherapy Utility in Psoriasis
© 2024 MJH Life Sciences

All rights reserved.